Modality
Vaccine
MOA
PRMT5i
Target
KRASG12C
Pathway
JAK/STAT
CLL
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Jun 2030
Phase 2Current
NCT03951302
2,090 pts·CLL
2018-02→2030-06·Recruiting
NCT03742985
885 pts·CLL
2017-01→2025-03·Active
2,975 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-211.0y agoPh3 Readout· CLL
2030-06-184.2y awayPh3 Readout· CLL
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-03-21 · 1.0y ago
CLL
Ph3 Readout
2030-06-18 · 4.2y away
CLL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03951302 | Phase 2/3 | CLL | Recruiting | 2090 | LiverFat |
| NCT03742985 | Phase 2/3 | CLL | Active | 885 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |